Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Zinc finger translocation-associated protein (ZFTA) is a nuclear protein coded by the ZFTA gene, previously known as C11orf95[4][7]. It is involved in the regulation of gene transcription and is predicted to participate in chromatin remodeling and negative regulation of DNA-templated transcription[1][4]. ZFTA is best known for its role in aggressive pediatric brain tumors, where it forms oncogenic fusion genes—most infamously, ZFTA-RELA (RELA proto-oncogene, NF-κB subunit)—that drive aberrant gene expression via unique epigenetic mechanisms, particularly in RELA fusion-positive ependymomas, a subset of central nervous system tumors[3][5][8]. As a result, detection of ZFTA fusions serves as a critical molecular biomarker for diagnosis and subclassification of ependymoma, though no direct pharmacological inhibitors of ZFTA are in clinical use or widely reported research[3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Zinc finger translocation-associated protein (ZFTA).